UCB Revenue and Competitors
Estimated Revenue & Valuation
- UCB's estimated annual revenue is currently $3.7B per year.
- UCB's estimated revenue per employee is $201,000
Employee Data
- UCB has 18588 Employees.
- UCB grew their employee count by 4% last year.
UCB's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EA to CEO | Reveal Email/Phone |
2 | CEO & Chairman the Executive Committee | Reveal Email/Phone |
3 | VP | Reveal Email/Phone |
4 | CFO | Commercial Finance | Reveal Email/Phone |
5 | Executive Assistant to VP Head Group Finance | Reveal Email/Phone |
6 | Sr. Associate Director, Learning & Development Capability Owner | Reveal Email/Phone |
7 | Executive Assistant to VP Head Talent Acquisition, Learning & Development | Reveal Email/Phone |
8 | Regulatory Process & Data Owner | Reveal Email/Phone |
9 | Assistant to VP & Head Talent Acquisition & Development | Reveal Email/Phone |
10 | Chief Accountant | Reveal Email/Phone |
UCB Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $29.7M | 148 | 8% | N/A | N/A |
#2 | $10.5M | 52 | -2% | N/A | N/A |
#3 | $11.3M | 56 | 4% | N/A | N/A |
#4 | $29.1M | 145 | 21% | N/A | N/A |
#5 | $6.8M | 34 | -6% | N/A | N/A |
#6 | $18.1M | 90 | -35% | N/A | N/A |
#7 | $48.2M | 240 | 37% | N/A | N/A |
#8 | $1.2M | 12 | 140% | $50M | N/A |
#9 | $12.5M | 62 | -9% | N/A | N/A |
#10 | $10.1M | 50 | -2% | N/A | N/A |
What Is UCB?
UCB aspires to be the patient-centric global biopharmaceutical leader, transforming the lives of people living with serious diseases. The company employs more than 8 000 people dedicated to the research, development and commercialisation of innovative medicines and patient solutions. Operating in more than 40 countries, UCB generated revenues of € 3.2 billion in 2011.
keywords:N/A
N/A
Total Funding
18588
Number of Employees
$3.7B
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
UCB News
UCB's General Meeting of Shareholders 2022. For financial year 2021: Gross dividend of 1.30 per share (+ 2.36%), payable 3 May 2022; All...
Julia Amunts of PeakProfiling Working alongside the team of UCB will support us in validating our voice technology that can potentially act...
According to Zacks, UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for...
SUMMIT, N.J.--(BUSINESS WIRE)--Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced today the closing of its $23 million Series A financing round. Engage will use the proceeds fr ...
SUMMIT, N.J.--(BUSINESS WIRE)--Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced today the closing of its $23 million Series A financing round. Engage will use the proceeds fr ...